SCHEDULE: DAFNA Capital Management Boosts Stake in Stereotaxis

DAFNA Capital Management, through its affiliated entities, has increased its beneficial ownership in Stereotaxis, Inc. to 15.3% following the purchase of convertible promissory notes.

Summary

• DAFNA Capital Management, LLC, along with its affiliated entities (Dr. Nathan Fischel, Dr. Fariba Ghodsian, DAFNA LifeScience, L.P., and DAFNA LifeScience Select, L.P.), has filed an amendment to its Schedule 13D, reporting an increased beneficial ownership in Stereotaxis, Inc.
• The Reporting Persons collectively hold 15,628,395 shares of Common Stock, representing approximately 15.3% of the outstanding shares.
• This increase is primarily due to the purchase of $2,000,000 in convertible promissory notes from Stereotaxis, Inc. on November 9, 2026.
• These notes are convertible into 1,652,892 shares of Common Stock at an initial conversion rate of $1.21 per share, subject to a 19.9% beneficial ownership limitation.
• Dr. Nathan Fischel, as a member of Stereotaxis' Board of Directors, also holds 294,949 vested or soon-to-be-vested restricted common shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting increased investment and potential future upside, but with inherent risks associated with convertible notes and beneficial ownership limitations.

Positives

• Increased investment in Stereotaxis, Inc. by DAFNA Capital Management and its affiliates, indicating confidence in the company's future prospects.
• Acquisition of $2,000,000 in convertible promissory notes, providing potential for future equity ownership.
• Dr. Nathan Fischel's continued role on the Board of Directors, with vested or near-vesting restricted stock, aligns his interests with the company.
• The aggregate beneficial ownership of 15.3% suggests a significant stake and potential for influence.

Negatives

• The convertible notes are subject to a 19.9% beneficial ownership limitation, which could restrict the full conversion of shares.
• The convertible preferred stock held by the Funds is subject to a 4.99% beneficial ownership limitation and is currently unable to be converted.
• The filing is an amendment to a previous filing, indicating ongoing changes in beneficial ownership rather than a single, definitive event.

Risks

• Potential dilution to existing shareholders if the convertible notes are fully converted.
• The beneficial ownership limitations (19.9% and 4.99%) may prevent the Reporting Persons from converting their full investment into equity.
• The value of the investment is tied to the performance of Stereotaxis, Inc.'s stock price.
• Changes in beneficial ownership can sometimes signal activist intentions or potential strategic shifts, which may create uncertainty.

Future Outlook

The filing indicates a future potential increase in beneficial ownership through the conversion of convertible promissory notes, subject to beneficial ownership limitations. The company's performance will dictate the ultimate conversion and value realization.

Management Comments

• DAFNA Capital Management, LLC, Dr. Nathan Fischel, and Dr. Fariba Ghodsian disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest.
• This report shall not be deemed an admission that DAFNA, Dr. Fischel or Dr. Ghodsian is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

StockSavvy.ai notes that the use of convertible notes is a common strategy for investors seeking to gain exposure to a company with potential upside while mitigating immediate equity risk. The beneficial ownership limitations are a standard regulatory feature to prevent excessive control.

Comparison to Industry Standards

• The 19.9% beneficial ownership limitation is a common threshold in many jurisdictions and for many investment funds to avoid triggering mandatory takeover bids or specific regulatory scrutiny that might apply above certain ownership percentages.
• The 10% interest rate on the convertible notes is within the typical range for such instruments, reflecting the risk profile and market conditions at the time of issuance.
• The structure of DAFNA Capital Management, LLC acting as investment manager and general partner for investment funds (LifeScience and Select) is a standard operational model in the asset management industry.

Stakeholder Impact

• Shareholders: Potential dilution if notes are converted; increased stake by a significant investor may influence corporate strategy.
• Creditors: The issuance of convertible notes may affect the company's debt-to-equity ratio and financial leverage.
• Management: Increased scrutiny or potential influence from a significant beneficial owner.

Next Steps

• The Reporting Persons may convert the principal and accrued interest of the Notes into shares of Stereotaxis, Inc.'s Common Stock at their election, subject to beneficial ownership limitations.
• Continued monitoring of Stereotaxis, Inc.'s performance and any further changes in beneficial ownership by the Reporting Persons.

Key Dates

Recommendation

The increased stake and investment via convertible notes suggest a positive outlook from DAFNA Capital Management. However, the beneficial ownership limitations and the nature of convertible debt warrant a cautious 'hold' recommendation until conversion details and company performance become clearer.

Keywords

Schedule 13D, DAFNA Capital Management, Stereotaxis, Convertible Notes, Beneficial Ownership, Investment Funds, Equity Investment, SEC Filing